Key Takeaways CLB's Q3 EPS of 22 cents beat estimates but fell from last year's 27 cents due to segment underperformance.Revenues rose to $134.5M, driven by global demand for analytical and diagnostic services.CLB kept debt low, bought back shares and sees steady long-term demand from deepwater projects.Core Laboratories Inc. (CLB) reported third-quarter 2025 adjusted earnings of 22 cents per share, which beat the Zacks Consensus Estimate of 19 cents. This can be attributed to the outperformance of the Prod ...